Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Tofacitinib> ?p ?o. }
Showing items 1 to 71 of
71
with 100 items per page.
- Tofacitinib abstract "Tofacitinib (trade names Xeljanz and Jakvinus, formerly tasocitinib, CP-690550) is a drug of the janus kinase (JAK) inhibitor class, discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and Russia, and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. Tofacitinib was not approved by the European regulatory agencies because of concerns over efficacy and safety.".
- Tofacitinib atcPrefix "L04".
- Tofacitinib atcSuffix "AA29".
- Tofacitinib bioavailability "74.0".
- Tofacitinib casNumber "477600-75-2".
- Tofacitinib chEBI "71200".
- Tofacitinib drugbank "DB08183".
- Tofacitinib fdaUniiCode "87LA6FU830".
- Tofacitinib iupacName "3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile".
- Tofacitinib pubchem "9926791".
- Tofacitinib thumbnail Tofacitinib2DACS.svg?width=300.
- Tofacitinib wikiPageID "30805678".
- Tofacitinib wikiPageRevisionID "606232451".
- Tofacitinib atcPrefix "L04".
- Tofacitinib atcSuffix "AA29".
- Tofacitinib bioavailability "74.0".
- Tofacitinib c "16".
- Tofacitinib casNumber "477600".
- Tofacitinib chebi "71200".
- Tofacitinib chembl "221959".
- Tofacitinib chemspiderid "8102425".
- Tofacitinib date "November 2012".
- Tofacitinib drugbank "DB08183".
- Tofacitinib eliminationHalfLife "10800.0".
- Tofacitinib excretion "Urine".
- Tofacitinib h "20".
- Tofacitinib hasPhotoCollection Tofacitinib.
- Tofacitinib inchi "1".
- Tofacitinib inchikey "UJLAWZDWDVHWOW-YPMHNXCEBF".
- Tofacitinib iupacName "3".
- Tofacitinib legalUs "Rx-only".
- Tofacitinib licenceUs "Tofacitinib".
- Tofacitinib metabolism "Hepatic".
- Tofacitinib molecularWeight "312.369".
- Tofacitinib n "6".
- Tofacitinib o "1".
- Tofacitinib pregnancyUs "C".
- Tofacitinib proteinBound "40.0".
- Tofacitinib pubchem "9926791".
- Tofacitinib reason "The clinical trials descriptions need to be updated".
- Tofacitinib routesOfAdministration "Oral".
- Tofacitinib smiles "CC2CCNCC2Nc3ncnc1nccc13".
- Tofacitinib stdinchi "1".
- Tofacitinib stdinchikey "UJLAWZDWDVHWOW-YPMHNXCESA-N".
- Tofacitinib synonyms "CP-690550".
- Tofacitinib tradename "Xeljanz, Jakvinus".
- Tofacitinib unii "87".
- Tofacitinib subject Category:Non-receptor_tyrosine_kinase_inhibitors.
- Tofacitinib type Agent114778436.
- Tofacitinib type CausalAgent100007347.
- Tofacitinib type Drug103247620.
- Tofacitinib type Matter100020827.
- Tofacitinib type Medicine103740161.
- Tofacitinib type Non-receptorTyrosineKinaseInhibitors.
- Tofacitinib type PhysicalEntity100001930.
- Tofacitinib type Substance100020090.
- Tofacitinib type TyrosineKinaseInhibitor104506005.
- Tofacitinib type Drug.
- Tofacitinib type FunctionalSubstance.
- Tofacitinib comment "Tofacitinib (trade names Xeljanz and Jakvinus, formerly tasocitinib, CP-690550) is a drug of the janus kinase (JAK) inhibitor class, discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and Russia, and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection.".
- Tofacitinib label "Tofacitinib".
- Tofacitinib label "Tofacitinib".
- Tofacitinib sameAs Tofacitinib.
- Tofacitinib sameAs トファシチニブ.
- Tofacitinib sameAs m.0gfhs9b.
- Tofacitinib sameAs Q3530324.
- Tofacitinib sameAs Q3530324.
- Tofacitinib sameAs Tofacitinib.
- Tofacitinib wasDerivedFrom Tofacitinib?oldid=606232451.
- Tofacitinib depiction Tofacitinib2DACS.svg.
- Tofacitinib isPrimaryTopicOf Tofacitinib.